Key CYP2C19-ID test performance milestone achieved | 21-May-2024 | 11:00 | RNS |
Amendment to Open Offer timetable | 15-May-2024 | 07:00 | RNS |
Publication of Circular and Notice of GM | 14-May-2024 | 07:00 | RNS |
Completion of placing | 10-May-2024 | 07:00 | RNS |
Proposed REX Retail Offer | 09-May-2024 | 16:49 | RNS |
Proposed Fundraise for a minimum of £6.0 mi... | 09-May-2024 | 16:48 | RNS |
Clinical Trial Agreement | 24-Apr-2024 | 15:36 | RNS |
Application for Listing & Total Voting Rights | 03-Apr-2024 | 17:00 | RNS |
NICE recommends the Genedrive CYP2C19-ID Kit | 03-Apr-2024 | 07:00 | RNS |
Half-year Report | 28-Mar-2024 | 07:00 | RNS |
Application for Listing & Total Voting Rights | 19-Mar-2024 | 15:53 | RNS |
Receipt of R&D tax credit | 15-Mar-2024 | 12:30 | RNS |
NICE Early Value Assessment update | 19-Feb-2024 | 07:00 | RNS |
Director/PDMR Shareholding | 06-Feb-2024 | 14:03 | RNS |
Total Voting Rights | 02-Feb-2024 | 15:35 | RNS |
Currency | UK Pounds |
Share Price | 1.68p |
Change Today | 0.025p |
% Change | 1.52 % |
52 Week High | 20.50 |
52 Week Low | 1.60 |
Volume | 13,900,258 |
Shares Issued | 154.32m |
Market Cap | £2.58m |
RiskGrade | 747 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
16:00 | 500 @ 1.65p |
15:58 | 250,000 @ 1.70p |
15:57 | 5 @ 1.70p |
15:53 | 58,568 @ 1.70p |
15:48 | 1,500 @ 1.65p |
You are here: research